[IMAGES BELOW] Sustained complete resolution of temporal lobe brain metastasis and continued orbital tumor reduction after >18 months of treatment“Eye bulging” metastatic breast cancer patient had failed 8 prior regimens, including antibody-drug conjugate (ADC) therapyPatient remains on BriaCell’s Phase 2 study with 29 treatment cycles completed PHILADELPHIA and VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or t ...

The SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.What Are Smart Beta ETFs?The ETF industry has traditionally been dominated by products based on market capitalization weighted indexes that are designed to represent the market or a particular segment of the market.Investors who believe in market efficiency should consider market cap indexes, as they replicate market returns in a lo ...

– Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findings support the inclusion of key secondary endpoints assessing cognition and behavior in the Phase 3 EMPEROR study and contrast with outcomes observed in natural history data – CAMBRIDGE, Mass. and BEDFORD, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechn ...

PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (“Passage Bio” or the “Company”) (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that its Board of Directors (“Board”) has approved a reverse stock split of the company’s outstanding shares of common stock at a ratio of 1-for-20. The reverse stock split will become effective at 12:01 a.m. Eastern time on July 14, 2025. Passage Bio’s common s ...

REYKJAVIK, Iceland, July 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Linda Jónsdóttir as Chief Financial Officer (CFO). Linda is a highly experienced international executive with a strong background in finance and corporate leadership. She has held senior roles across a range of industries, including banking, food technology, transportation, an ...

Core Insights - Henlius is a leading Chinese biopharmaceutical company focused on R&D with six products approved for marketing in China and four products successfully entering international markets [1][4] - The company's pipeline emphasizes oncology and autoimmune diseases, featuring innovative candidates like HLX43 (PD-L1 ADC) and HLX22 (anti-HER2 monoclonal antibody) [1][2] Product Development - HLX43 is the first PD-L1 ADC globally to enter Phase II clinical trials, showing promising efficacy with an objective response rate (ORR) of 75% in thymic squamous cell carcinoma (TSCC) patients and 40% in squamous non-small cell lung cancer (sqNSCLC) patients [1] - HLX22, a novel anti-HER2 monoclonal antibody, is expected to redefine the standard of care for first-line HER2-positive gastric cancer, with ongoing Phase III trials in combination with trastuzumab and chemotherapy [2] Market Performance - Hansizhuang (Serplulimab) has achieved rapid domestic sales growth, reaching Rmb1.31 billion in 2024, and has been approved in multiple international markets [3] - The company has successfully entered global markets with four products, including Hanlikang and Hanquyou, and has established collaborations for the commercialization of various biosimilars [4] Financial Projections - Revenue forecasts indicate growth to Rmb5.96 billion in 2025, Rmb6.36 billion in 2026, and Rmb7.02 billion in 2027, with net profits projected at Rmb790 million, Rmb900 million, and Rmb1.14 billion respectively [5]

活动背后，正是西湖区与西湖大学"区校共生"模式的生动演绎——姜汉卿团队研发的柔性变刚度机 械臂，从机械臂细分赛道突围，已斩获韩国订单；李旭团队研发的"高维生物学+AI驱动药物发现平 台"，摘得2025国际生物医疗创赛的创新大奖；王睿团队带来的钙钛矿太阳能电池为新能源汽车、无人 机等提供全新解决方案……这些前沿领域的科技成果，是西湖大学成果转化图谱的一角。据统计，西湖 大学孵化项目已有42家落地西湖区，总估值近180亿元，成为区域经济高质量发展的核心引擎。 近日，西湖区为企服务品牌活动"西湖链链看"迎来西湖大学科技成果转化专场。现场，西湖交互与 遐龄荟、西湖心辰与西湖康养集团、西湖阳光与之江城投集团等7对"CP"达成战略合作，涵盖智慧康 养、光储设备、生命健康等领域。 这些硬科技正在加速走进大众生活，展现了从实验室到市场的转化速度。"模块化设计适配90%的 人形机器人及轮椅、护理床等设备，由于机械臂的柔性设计，未来可广泛应用于医疗和家庭服务等多种 场景。"西湖交互有关负责人黄紫虹说，让实验室技术真正服务社会，企业正积极对接西湖区内的康养 场景。 数据的说服力更为直观：西湖区已连续三年夺得"科技创新鼎"，科技成果 ...

It is time. It's time for the light round but round the stock by sore stock and then the lightning round is over. Are you ready ski daddy.Time for the light round. Let's go to Mark in New York. Mark.So Jim, I recently joined the club and I find that I'm learning a lot from it. So it's great. Excellent.Thank you. Thank you. As a as a club member, I I know that you've recommended some pharmaceutical companies based on their developing new drugs, but I don't remember you ever recommending a biotech company.So, ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, July 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) investors of a class action representing investors that bought securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period"). Iovance investors have until July 14, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F ...

Core Insights - The article emphasizes the importance of quantitative research, financial modeling, and risk management in equity valuation and market trends [1] - It highlights the experience of the analyst in leading teams for model validation and stress testing, showcasing a strong background in both fundamental and technical analysis [1] - The collaboration between the analyst and their research partner aims to provide high-quality, data-driven insights for investors [1] Company and Industry Analysis - The focus is on uncovering high-growth investment opportunities through rigorous risk management and a long-term perspective on value creation [1] - There is a particular interest in macroeconomic trends, corporate earnings, and financial statement analysis, which are crucial for providing actionable investment ideas [1]